Immune reset: CAR-T therapy takes on lupus

NCT ID NCT06310811

Terminated Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a new treatment called RD06-04, a CAR-T cell therapy, in 12 people with moderate to severe lupus. The therapy aims to target and reset immune cells that attack the body. The main goal is to check safety and find the right dose, with a close watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RD06-04 cells (a type of CAR-T cell therapy that targets CD19 on immune cells)
What this could lead to: If it works, this could point toward a new way to control lupus by resetting the immune system, potentially reducing the need for lifelong medication.
What could go wrong: This is a very early, small Phase I trial with only 12 participants. It is currently suspended, and the main goal is safety, not proof of effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFECTIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFFECTIVE SAFETY

Contacts and locations

Locations

Wuhan Union

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.